Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ardent: IMR-687 (Tovinontrine) in Sickle Cell Disease
NCT04474314Phase 2Terminated
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of tovinontrine in sickle cell disease (SCD), sponsored by Cardurion Pharmaceuticals. Started Aug 2020; status: terminated.
02
Drugs
tovinontrine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04474314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474314.